Literature DB >> 32946993

Role of Nrf2 and mitochondria in cancer stem cells; in carcinogenesis, tumor progression, and chemoresistance.

Zahra Payandeh1, Abbas Pirpour Tazehkand2, Ghasem Barati3, Farhad Pouremamali4, Houman Kahroba5, Behzad Baradaran6, Nasser Samadi7.   

Abstract

Cancer stem cells (CSCs) are rare sub-population in tumor mass with self-renewal and differentiation abilities; CSCs are considered as the main cells which are responsible for tumor metastasis, cancer recurrence, and chemo/radio-resistance. CSCs are believed to contain low mitochondria in quantity, high concentration of nuclear factor erythroid 2-related factor 2 (Nrf2), and low reactive oxygen species (ROS) levels. Mitochondria regulate certain cellular functions, including controlling of cellular energetics, calcium signaling, cell growth and cell differentiation, cell cycle regulation, and cell death. Also, mitochondria are the main sources of intrinsic ROS production. Dysfunction of CSCs mitochondria due to oxidative phosphorylation is reported in several pathological conditions, including metabolic disorders, age-related diseases, and various types of cancers. ROS levels play a significant role in cellular signal transduction and CSCs' identity and differentiation capability. Nrf2 is a master transcription factor that plays critical functions in maintaining cellular redox hemostasis by regulating several antioxidant and detoxification pathways. Recently, the critical function of Nrf2 in CSCs has been revealed by several studies. Nrf2 is an essential molecule in the maintenance of CSCs' stemness and self-renewal in response to different oxidative stresses such as chemotherapy-induced elevation of ROS. Nrf2 enables these cells to recover from chemotherapy damages, and promotes establishment of invasion and dissemination. In this study, we have summarized the role of Nrf2 and mitochondria function CSCs, which promote cancer development. The significant role of Nrf2 in the regulation of mitochondrial function and ROS levels suggests this molecule as a potential target to eradicate CSCs.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  CSCs; Mitochondria; Nrf2; Oncogene; ROS

Mesh:

Substances:

Year:  2020        PMID: 32946993     DOI: 10.1016/j.biochi.2020.09.014

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  10 in total

1.  The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance and Migration in Colon Cancer Cells.

Authors:  Zahra Payandeh; Abbas Pirpour Tazehkand; Behzad Mansoori; Vahid Khaze; Milad Asadi; Behzad Baradaran; Nasser Samadi
Journal:  Avicenna J Med Biotechnol       Date:  2021 Jul-Sep

2.  N-Acetylcysteine Reduces miR-146a and NF-κB p65 Inflammatory Signaling Following Cadmium Hepatotoxicity in Rats.

Authors:  Rasha S Albeltagy; Farah Mumtaz; Ahmed E Abdel Moneim; Ola H El-Habit
Journal:  Biol Trace Elem Res       Date:  2021-01-17       Impact factor: 3.738

Review 3.  Mitochondria: Insights into Crucial Features to Overcome Cancer Chemoresistance.

Authors:  Ilaria Genovese; Marianna Carinci; Lorenzo Modesti; Gianluca Aguiari; Paolo Pinton; Carlotta Giorgi
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

4.  Taxifolin, Extracted from Waste Larix olgensis Roots, Attenuates CCl4-Induced Liver Fibrosis by Regulating the PI3K/AKT/mTOR and TGF-β1/Smads Signaling Pathways.

Authors:  Xinglong Liu; Wencong Liu; Chuanbo Ding; Yingchun Zhao; Xueyan Chen; Dong Ling; Yinan Zheng; Zhiqiang Cheng
Journal:  Drug Des Devel Ther       Date:  2021-02-26       Impact factor: 4.162

5.  Cancer Stem-Like Phenotype of Mitochondria Dysfunctional Hep3B Hepatocellular Carcinoma Cell Line.

Authors:  Yu-Seon Han; Eui-Yeun Yi; Myeong-Eun Jegal; Yung-Jin Kim
Journal:  Cells       Date:  2021-06-27       Impact factor: 6.600

6.  Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway.

Authors:  Kuen-Jang Tsai; Hsin-Yi Tsai; Chin-Chuan Tsai; Tai-Yu Chen; Tsung-Hua Hsieh; Chun-Lin Chen; Lulekiwe Mbuyisa; Yaw-Bin Huang; Ming-Wei Lin
Journal:  Molecules       Date:  2021-10-26       Impact factor: 4.411

Review 7.  Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.

Authors:  Ping Jin; Jingwen Jiang; Li Zhou; Zhao Huang; Edouard C Nice; Canhua Huang; Li Fu
Journal:  J Hematol Oncol       Date:  2022-07-18       Impact factor: 23.168

8.  Categorizing the characteristics of human carcinogens: a need for specificity.

Authors:  Carr J Smith; Thomas A Perfetti; A Wallace Hayes; Sir Colin Berry; James E Trosko; Judy A King; Jay I Goodman; C Glenn Begley; Anthony Dayan
Journal:  Arch Toxicol       Date:  2021-06-20       Impact factor: 5.153

Review 9.  Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.

Authors:  Ieman A M Aljahdali; Renyuan Zhang; Fengzhi Li; Kent L Nastiuk; John J Krolewski; Xiang Ling
Journal:  J Exp Clin Cancer Res       Date:  2021-08-12

10.  MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice.

Authors:  Tania Capeloa; Joanna Krzystyniak; Amanda Canas Rodriguez; Valéry L Payen; Luca X Zampieri; Erica Pranzini; Françoise Derouane; Thibaut Vazeille; Caroline Bouzin; François P Duhoux; Michael P Murphy; Paolo E Porporato; Pierre Sonveaux
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.